MolMet Figure 6: Higher blood cholesterol and lower fasting blood glucose and insulin in P446L mice on high energy diets.

A-F) Chronic study of P446L mice on HFD: A. Experimental design. B) Body weight, liver weight and epididymis fat pad weight, (n=7,7). C) No difference in free-feeding blood glucose and insulin (21 wk, n=7,7) or glucose tolerance (4-wk, GTT, n=9,9). D) Higher blood cholesterol and liver triglyceride by LL genotype but no difference in blood triglyceride or liver cholesterol (n=6-7). E) Representative hematoxylin-eosin images showing microvesicular steatosis in LL-genotype. F) Histopathology scores for steatosis, microvesicular steatosis, lipogranulomas, lobular Inflammation, portal Inflammation and fibrosis showing higher microvesicular steatosis by LL genotype (n=7,7). G-L) Chronic study of P446L mice on HFHSD: G. Experimental design. H. Body weight, liver weight and higher epididymal fat pad wt by LL genotype, n=11-13. I) Free feeding blood glucose and insulin and glucose tolerance test (GTT), n=11-14. J) Lower post-prandial blood glucose (2h food withdrawal) and insulin and inorganic phosphate (Pi) at cull, n=10-14. K) Higher blood cholesterol in LL genotype but no difference in blood triglycerides or liver triglycerides and cholesterol, n=10-14. L) Histopathology scores showing higher lipogranuloma and lower fibrosis scores by LL genotype, n=14,13. M) Representative hematoxylin-eosin images showing lipogranulomas and Sirius red fast green (SRFG) for fibrosis staining. Categorical data statistical differences was by Chi Square test; other analysis was by t-test #P